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Abstract
Objectives: Dickkopf-1 (DKK1) is a potent inhibitor of Wnt signalling, which exerts anabolic effects on bone and also takes
part in the regulation of vascular cells. Our aims were to evaluate serum DKK1 in type 2 diabetes (T2DM) patients and to
analyze its relationships with cardiovascular disease (CVD). We also evaluated the relationship between DKK1 and bone
metabolism.
Design: We conducted a cross-sectional study in which we measured serum DKK1 (ELISA, Biomedica) in 126 subjects: 72
patients with T2DM and 54 non-diabetic subjects. We analysed its relationship with clinical CVD, preclinical CVD expressed
as carotid intima media thickness (IMT), and bone metabolism.
Results: T2DM patients with CVD (P= 0,026) and abnormal carotid IMT (P= 0,038) had higher DKK1 concentrations. DKK1
was related to the presence of CVD in T2DM, independently of the presence of risk factors for atherosclerosis. Therefore, for
each increase of 28 pg/ml of serum DKK1 there was a 6,2% increase in the risk of CVD in T2DM patients. The ROC curve
analysis to evaluate the usefulness of DKK1 as a marker for high risk of CVD showed an area under the curve of 0,667 (95%
CI: 0,538–0,795; P= 0,016). In addition, there was a positive correlation between serum DKK1 and spine bone mineral density
in the total sample (r = 0,183; P= 0,048).
Conclusion: In summary, circulating DKK1 levels are higher in T2DM with CVD and are associated with an abnormal carotid
IMT in this cross-sectional study. DKK1 may be involved in vascular disease of T2DM patients.
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Introduction
Patients with type 2 diabetes mellitus (T2DM) have a higher risk
of cardiovascular disease (CVD). This association has serious
consequences on the morbidity and the mortality in this
population. Atherosclerosis is the main pathological mechanism
in macrovascular disease in T2DM, which causes the development
of atheroma plaques and the major life-threatening events in
atherosclerosis, including myocardial infarction and stroke [1].
Patients with osteoporosis have a higher prevalence of
cardiovascular disease, and it has been proposed that both
pathologies share common pathophysiologic pathways [2]. In
T2DM there is an increased risk of fractures at any skeletal site
even with greater bone mineral density (BMD) [3,4], and there are
data from epidemiological studies supporting a relationship
between low bone mineral density (BMD) and atherosclerosis in
T2DM [5,6]. Thus, a better characterization of the pathways that
could be involved in both processes is of interest, and may help in
the development of new therapeutic tools.
The Wnt signalling pathways are involved in several develop-
mental and physiological processes, including the cell differenti-
ation and tissue/organ morphogenesis [7]. The discovery of the
Wnt signaling pathway and its relevance in bone homeostasis has
contributed to a better knowledge of the cellular and molecular
mechanisms of bone biology [8]. The activation of this pathway
results in an expansion of osteoprogenitor cells and also determines
a reduction in the apoptosis of osteoblasts, which leads to anabolic
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effects on bone [8]. The canonical Wnt pathway is regulated by
several families of secreted antagonists, such as the soluble frizzled-
related receptors, dickkopf-1 (DKK1) and sclerostin. DKK1
regulates the Wnt signaling by binding to the Wnt co-receptor,
the low-density lipoprotein-related receptor (LRP) 5/6. In addition
to its binding to LRP 5/6, DKK1 binds to other trans-membrane
molecules as proteins Kremen, which increases their inhibitory
activity on the Wnt signaling pathway [9].
The role of Wnt signaling pathways in atherosclerosis it is a
matter of growing interest. In preclinical studies the Wnt signaling
pathways are involved in atherosclerosis-related processes as
vascular calcification [10], inflammation [11], and the monocyte
adhesion and its trans-endothelial migration [12]. In a recent study
conducted in bovine aortic endothelial cells (ECs) [13], the authors
found that Msx2 and Wnt7 family members stabilize the aortic
ECs phenotype, whereas DKK1 promotes an endothelial–
mesenchymal transition in cultured bovine aortic ECs, a process
associated to the pathogenesis of myocardial fibrosis with ischemia
[14] and valve calcification [15]. In addition, in animal models of
CKD-MBD (chronic kidney disease-mineral bone disease) [16]
there is an increased renal production of Wnt inhibitor family
members and higher levels of circulating DKK1, sclerostin, and
secreted klotho. In this model, the neutralization of DKK1 by
administration of a monoclonal antibody after renal injury
stimulated bone formation rates, corrected the osteodystrophy,
and prevented CKD-stimulated vascular calcification. Besides, the
neutralization of DKK1 suppressed aortic expression of the
osteoblastic transcription factor Runx2, increased expression of
vascular smooth muscle protein 22-a, and restored aortic
expression of klotho’’
There is also recent data showing a relationship between serum
DKK1 and atherosclerosis in humans [17,18]. In a previous study
from Register and colleagues, DKK1 concentrations were
inversely related to coronary artery disease and aortic calcification.
However, as the authors point, this study has been conducted in
Afro-Americans (AAs) with T2DM, which has a different
prevalence of atherosclerotic disease and osteoporosis compared
to European populations. These differences make it interesting to
explore this relationship in Caucasian type 2 diabetes. Besides, the
relationship between DKK1 concentrations and bone mass has
been explored with conflicting data [19–21], so its evaluation in a
population with a high risk of bone fragility such as T2DM is of
interest.
In this context, the objectives of our study were to evaluate
serum DKK1 levels in a cohort of T2DM patients and to analyze
its relationships with CVD and bone metabolism. In addition, we
compared serum DKK1 concentrations between T2DM and non-
diabetic subjects. Thus, our hypothesis was that DKK1 concen-
trations may be related to CVD and bone metabolism in T2DM
patients.
Materials and Methods
Study population
Our study was a cross-sectional one that included 126 subjects.
The estimated size of the sample considering an error of 5% and a
statistical power of 80% was 84 subjects. The T2DM group
included 72 patients with a diagnosis of diabetes according to the
American Diabetes Association criteria (ADA, 2005). From
January 2006 to December 2007 we consecutively recruited
patients who had been referred to our outpatient clinic from
community clinics for treatment of diabetes. The control group
included 54 non-diabetic subjects who were consecutively
recruited from the general community in the same period of time.
All participants were recruited according to the following
criteria: Caucasian, free-living, aged 35 to 65 years and normal
values for blood count, renal creatinine, hepatic function, calcium
and phosphorus. We considered as exclusion criteria the presence
of chronic diseases apart from T2DM in the non-diabetic group,
the presence of diseases affecting bone (Paget’s disease, rheuma-
toid arthritis, hyperparathyroidism, hypercortisolism, malignant
tumors, renal bone disease, chronic liver disease and post-
transplantation bone disease) and also previous or current
treatment with drugs affecting bone metabolism (calcium supple-
ments, vitamin D preparations, selective estrogen receptor
modulators, calcitonin, estrogens therapy, antiresorptive therapy,
thiazides, steroids, glucocorticoids or anticonvulsants). Patients
treated with thiazolidinediones were also excluded.
The presence of cardiovascular disease was recorded by the
medical history and after that it was checked in medical records.
T2DM patients were classified into two groups according to the
presence of clinical CVD: CVD group and non-CVD group.
Inclusion criteria for patients with CVD were cerebrovascular
disease (ischemic stroke or transient ischemic attack); coronary
heart disease (previous myocardial infarction, diagnosed stable or
unstable angina, or coronary revascularization surgery) or
ischemic peripheral arterial disease (diagnosed by a positive
Doppler ultrasound or arteriogram, or by a previous revascular-
ization surgery).
The study was approved by the ethical review board of the
Hospital Universitario San Cecilio and it was done conformed to
the ethical guidelines for research in humans. All the participants
in the study provided written informed consent after a full
explanation of the purpose of the study and the nature of all the
procedures that will be used in the study. Written informed
consent was approved for the ethical review board of our hospital,
and after that it was filed in the medical record of each patient.
Clinical evaluation
Height, weight, and waist circumference were measured at
baseline according to standard procedures. Weight was measured
to the nearest 100 grams using digital electronic scales. Height and
waist circumference were measured to the nearest 1 mm using a
stadiometer and a metal anthropometric tape, respectively. Body
mass index (BMI) in Kg/m2 was calculated as weight divided by
the square of height in meters.
Blood pressure was measured in a standardized manner. The
subjects remained at rest for at least 5 minutes, and after that
blood pressure was measured twice using a standard mercury
sphygmomanometer (12 centimeters long, 35 cm wide). The mean
of the two values was used for analysis. We defined hypertension
when blood pressure values were higher than 140/90 mmHg
and/or where subjects were on antihypertensive treatment.
The participants reported their alcohol use, smoking status and
their level of physical activity with a specific health questionnaire.
Patients were classified as having a significant alcohol intake if it
was higher than 40 grams/day in males and 24 grams/day in
women; smoking status was categorized as no tobacco use or
current tobacco use. Physical activity was collected through a
specific questionnaire in which study subjects scored their physical
activity on a scale from 0 (none) to 10 (sport more than one hour
four times per week). Based on the results, the study sample was
divided into two groups: sedentary (,5 on the scale) and no
sedentary ($5 on the scale).
Serum measurements
Samples of venous blood were taken in the morning after a
fasting overnight. The sera were stored at 280uC until examina-
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Table 1. Characteristics of the study population.
Total Group (n =126) T2DM Group (n=72)
Non-diabetic Group
(n=54) P Value
Age (years) 5766 5866 5567 0,018
Male/female (n) 62/64 39/33 25/29 0,472
Medical history
Duration of diabetes (years) - 13,767,6 -
Hypertension (%) 53,2 80,6 46,3 ,0,001
Dyslipidaemia (%) 65,9 94,4 70,4 ,0,001
Albuminuria (%) 20,5 35,0 4,0 0,006
Chronic kidney disease (KDOQI stages) (%)
Stage 1 51 52 52 0,938
Stage 2 46 44 48 0,815
Stage 3 3 4 0 0,155
Smoker or ex-smoker (%) 15,1 16,7 13 0,623
Alcohol (%) 8,7 6,9 11,1 0,104
Sedentarism (%) 47,6 55,6 37,0 0,048
Clinical evaluation:
BMI (kg/m2) 102,6612,4 31,465,7 29,365,9 0,043
Waist circumference (cm) 130620 106,4611,4 97,4611,9 ,0,001
SBP (mm Hg) 80613 134697 124617 0,002
DBP (mm Hg) 30,565,9 80612 79615 0,705
Serum parameters:
FPG (mg/dL) 137,2661,9 173660,1 89,4610,4 ,0,001
HbA1c (%) 6,762,2 861,9 4,860,4 ,0,001
GFR (MDR/CKD-EPI)(ml/min/1,73 m2) 92623 92623 93622 0,745
Calcium (mg/dL) 9,560,5 9,660,5 9,360,4 0,001
Phosphorus (mg/dL) 3,660,5 3,760,5 3,560,5 0,01
PTH (pg/mL) 43,6619,5 38,5618,4 50,4619,1 ,0,001
25(OH) D (ng/mL) 19,5611,3 17,8611,5 21,6610,9 0,06
Triglyceride (mg/dl) 1426121 169,96149,8 104,9647,7 ,0,001
HDL-c (mg/dl) 53,5615,5 49616 59,5612,5 ,0,001
LDL-c (mg/dl) 111,7635,5 96,9634,1 130,8627,4 ,0,001
DKK1 (pg/ml) 6296374 6696395 5756340 0,163
DXA parameters and VF:
BMD LS (g/cm2) 0,97760,148 0,95460,146 160,148 0,068
BMD FN (g/cm2) 0,82060,124 0,81760,132 0,82360,117 0,792
BMD TH (g/cm2) 0,90660,135 0,90360,145 0,91160,125 0,772
T-score LS 21,0861,36 21,361,3 0,8261,3 0,058
T-score FN 20,5561,01 20,661,04 20,4960,99 0,565
T-score TH 20,5560,98 20,6261 20,5160,92 0,557
Osteoporosis (%) 15,9 24,6 9,4 0,047
Morphometric VF (%) 23,0 30,3 20,0 0,274
Cardiovascular disease: 35,7 58,3 5,6 ,0,001
Cerebrovascular disease (%) 11,9 19,4 1,9 0,002
Coronary heart disease (%) 23,8 38,9 3,7 ,0,001
Peripheral artery disease (%) 7,9 13,9 0 0,005
Abnormal intima-media thickness (%) 35,7 54,2 11,1 ,0,001
Carotid plaques (%) 15,9 29,4 0 ,0,001
Data for continuous variables are presented as mean 6SD. Data for categorical variables are presented as numbers and/or percentages. The comparison between
groups was done by Student’s t test (continuous variables) or Chi-square test (categorical variables).
T2DM: type 2 diabetes mellitus; BMI: body mass index; SBP: sistolic blood pressure; DBP: diastolic blood pressure; FPG: fasting plasma glucose; HbA1c: glycated hemoglobin;
GFR: glomerular filtration rate; MDR/CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; PTH: parathormone; 25(OH) D: 25-hydroxyvitamin D; HDL-c: High-density
lipoprotein; LDL-c: Low-density lipoprotein; BMD: bone mineral density; LS: lumbar spine; FN: femoral neck; TH: total hip; VF: vertebral fractures.
doi:10.1371/journal.pone.0111703.t001
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tion. Fasting plasma glucose (FPG), glycated hemoglobin (HbA1c),
calcium, phosphorus and creatinine were measured using standard
automated laboratory techniques. Glomerular filtration rate (GFR)
was calculated by MDRD/CKD-EPI formula [22]. High-density
lipoprotein (HDL), low-density lipoprotein (LDL) cholesterol and
triglycerides (TGs) were measured by standard biochemical
methods. Dyslipidemia was defined according to third report of
the expert panel on detection, evaluation, and treatment of high
blood cholesterol in adults (ATP-III) criteria or current treatment
with statins.
Calciotropic hormones measurement included serum intact
parathormone (Two-site immunoassay for iPTH, Roche Diagnos-
tics SL, Barcelona, Spain; intra and interassay variability of 3%)
and 25-hydroxyvitamin D (25-OH-D, radioimmunoassay, Dia-
Sorin, Stillwater, Minnesota USA. Serum DKK1 was measured
using quantitative sandwich enzyme-linked immunosorbent assay
(ELISA) developed by Biomedica (Biomedica Medizinprodukte
GmbH and Co. KG, Wien, Austria) according to the manufac-
turer’s instructions. The Biomedica DKK-1 ELISA (BI-20412)
detects free DKK-1. Intra-assay and interassay variability were of
7% and 9%, respectively. DKK1 measurements are reported
throughout in pg/ml after conversion from pMol/L. 1 pMol/l is
equivalent to 28,68 pg/ml.
Bone density measurement and vertebral fractures
assessment
Bone mineral density at lumbar spine (LS) L2–L4, femoral neck
(FN) and total hip (TH) was performed in all patients by dual-
energy X-ray absorptiometry (DXA) using Hologic QDR 4500
densitometer (Whatman, MA; variation coefficient ,1%). All the
BMD measurements were done by the same experienced operator.
We used the World Health Organization criteria for osteoporosis
(Kanis JA, 1994).
Standardized spinal X-rays were taken for morphometric
analysis of all participants of the study and they were interpreted
according to the algorithm developed by McCloskey and
colleagues [23].
Carotid intima-media thickness Ultrasonographic exam-
ination of the carotid arteries was performed with patients in
supine position using Doppler ultrasonography (Toshiba Power-
Vision 6000). The maximum intima-media thickness (IMT) at the
carotid bifurcation (BIF) was determined between the near and far
walls of the carotid bifurcation on the right and left sides. Each
part was measured from views of both longitudinal and vertical
sections at the bifurcation. If a discrepancy was observed in the
measured values between longitudinal and vertical sections, the
smaller value was selected to avoid overestimation. BIF–IMT was
defined as the mean of the measurements from the right and left
sides. The value for each side was obtained from the mean of 10
wall measurements. The BIF–IMT, measured in millimeters (mm),
was considered pathological if it was $0.9 mm, and was
considered to be carotid atherosclerosis if the BIF–IMT was $
1.2 mm or 50% greater than the BIF–IMT in the adjacent area
[24]. Plaques were identified as calcified by findings of bright white
echoes on sonography. A single trained sonographer performed
the study in all subjects.
Statistical analysis
Data for continuous variables are presented as mean 6
standard deviation (SD). Data for categorical variables are
presented as numbers and/or percentages. Kolmogorov–Smirnov
test was used to test the normality of distribution of continuous
variables. The association between continuous variables was
described by Pearson’s or Spearman’s correlation coefficients.
The comparison of categorical variables among groups was
performed using Chi-square test or Fisher test. The comparison
of continuous variables among groups was performed using
unpaired Student’s t test or Mann-Whitney test. To determine
the independent variables which correlated with DKK1 (depen-
dent variable), the parameters that correlate significantly in
univariate analysis and other which are biologically linked to
DKK1 were tested in multiple backward model linear regression
analysis. Multiple backward model of logistic regression analysis
was performed to identify DKK1 as independent predictor for
CVD (dependent variable) in T2DM patients. The model included
established atherosclerotic risk factors (age, gender, body mass
index, hypertension, dislipidaemia, smoking, sedentarism, HbA1c,
GFR and intima-media thickness). CVD-defining parameters
(cerebrovascular disease, coronary heart disease or ischemic
peripheral arterial disease) were not included in the multiple
logistic regression model. The usefulness of serum DKK1 as a
marker of high risk of atherosclerotic disease in T2DM was
Figure 1. DKK1 serum levels in T2DM patients according to the presence of cardiovascular disease and abnormal intima-media
thickness. Between groups differences are indicated through a bar with the P-value given above.
doi:10.1371/journal.pone.0111703.g001
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analyzed using a receiver operating characteristic curve (ROC
Curve). A p value of less than 0,05 was considered to be significant
(two-tailed). Data were recorded and analyzed using SPSS version
18.0 software (SPSS Inc, Chicago, IL, USA).
Results
The clinical characteristics of the study population are
summarized in Table 1. Serum DKK1 was significantly higher
(P= 0,026) in T2DM patients with CVD (7576416 pg/ml)
compared with those without CVD (5476333 pg/ml). (Figure 1
and Table 2). T2DM patients with abnormal IMT (7566433 pg/
ml vs 5636322 pg/ml; P= 0,042) and cerebrovascular disease
(8546480 pg/ml vs 6256363; P= 0,045) had higher DKK1
concentrations. (Figure 1 and Table 2). However, we did not find
differences in DKK1 concentrations according to the presence of
carotid plaque (P= 0,522), coronary heart disease (P= 0,677) or
ischemic peripheral artery disease (P= 0,762).
A model of logistic regression analysis was performed using the
presence of CVD as a dependent variable. Independent variables
were serum DKK1 levels and risk factors for atherosclerosis (age,
gender, body mass index, hypertension, dislipidaemia, smoking,
sedentarism, HbA1c, GFR, and IMT). DKK1 levels were
independently associated with the presence of CVD in T2DM
(odds ratio: 1,062, 95% confidence interval: 1,003–1,125;
P= 0,04). Therefore, for each increase of 28 pg/ml of serum
DKK1 there was a 6,2% increased risk of CVD in T2DM
patients.
In the ROC curve analysis to evaluate the usefulness of DKK1
as a marker for high risk of CVD, the area under the curve was
0,667 (95% confidence interval: 0,538–0,795; P= 0,016) (Fig-
ure 2). A concentration of 494 pg/ml or higher showed a
sensitivity of 71,4% and a specificity of 60% to identify an
increased risk of CVD.
We found no differences in DKK1 between study groups:
T2DM 6696395 vs non-diabetic 5756340 pg/ml, P= 0,163.
Serum DKK1 concentrations were significantly higher in females
than in males in total sample (6976434 vs 5636293 pg/ml,
P= 0,046) and in T2DM group (7886493 vs 5696255 pg/ml,
P= 0,025) but were not significantly increased in control females
(5936335 vs 5536349 pg/ml, P= 0,682).
Linear regression analysis was performed to determine the
influence of independent factors identified in univariate correla-
tion analysis, including group, gender, age, HbA1c, CVD and
IMT as independent variables that explain serum DKK1 levels.
The analysis demonstrated that gender (b=20,299, P= 0,002)
and CVD (b= 0,292, P= 0,007) were positively associated with
serum DKK1.
Regarding bone metabolism, lumbar spine BMD was positively
related to serum DKK1 in total sample (r = 0,183, P = 0,048). In
contrast, we did not found a significant relationship with bone
remodelling markers osteoporosis diagnosis or morphometric
vertebral fractures (data not shown), in the total sample or in the
study groups separately.
Discussion
To our knowledge, there is no previous study evaluating DKK1
concentrations and its relationship with CVD in Caucasian
T2DM patients. There is also scarce data concerning the
relationship between DKK1 and bone metabolism in T2DM.
Our results show that higher levels of DKK1 are associated with
clinical CVD and abnormal IMT in T2DM patients. These
findings suggest that serum DKK1 are related to the presence of
CVD in this population. However, our data showed no differences
in serum DKK1 between T2DM patients and non-diabetic
patients. Regarding bone metabolism, we found a significant
relationship with bone mineral density.
In our study, higher DKK1 levels were positively related to
cardiovascular disease in T2DM patients independently of the
presence of others risk factors for atherosclerosis, and high
concentrations of DKK1 were related to abnormal IMT in these
patients. Our results are in accordance with previous reports
showing the relationship between vascular disease and DKK1 in
other populations. Patients with cerebrovascular disease have
higher serum DKK1 levels compared with control subjects [25],
and serum DKK1 correlated with coronary artery calcification
and atherosclerotic plaques evaluated by coronary computed
tomography and coronary artery calcium scoring [17]. Previously,
Ueland and colleagues [26] demonstrated that DKK1 expression
is enhanced in advanced carotid plaques and that DKK1 is a novel
mediator in platelet-mediated endothelial cell activation, which
could occur within the atherosclerotic lesions. Moreover, current
data clearly demonstrate a novel role for Wnt proteins in the
proliferation, migration, and survival of smooth muscle cells
(SMCs) [27]. Regarding this, higher levels of DKK1 are present in
advanced carotid plaques and DKK1 promotes platelet-mediated
activation of endothelial cells. Thus, it has been proposed that this
could lead to enhanced inflammation in the atherosclerotic lesion;
however, it may also lead to a reduced survival, proliferation, and
migration of SMCs, thereby reinforcing the potential complexity
of the participation of Wnt proteins in atherosclerosis [27].
In contrast to our findings, DKK1 concentrations were
negatively associated with atherosclerotic calcified plaque in
African-Americans (AAs) patients with T2DM [18]. There are
several reasons that might contribute to this discrepancy. As the
authors point, AAs have lower rates of vascular calcification. It has
Table 2. DKK1 concentrations according to the presence of cardiovascular disease in the T2DM group.
Yes No P value
Cardiovascular disease 7576416 5476333 0,026
Cerebrovascular disease 8546480 6256363 0,045
Coronary heart disease 6946379 6546408 0,677
Peripheral artery disease 6346247 6756415 0,762
Abnormal intima-media thickness 7566433 5676322 0,042
Carotid plaque 7306422 6616395 0,522
The comparison between groups was done by Student’s t test.
doi:10.1371/journal.pone.0111703.t002
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been reported lower levels of coronary artery calcified plaque
relative to European Americans (EAs) despite similar or more
detrimental cardiovascular risk factor profiles [28,29]. This
observation is consistent both in T2DM and subjects without
diabetes [30,31], and suggests a differential impact of CV risk
factors on atherosclerosis based on ethnicity although the
underlying causes of ethnic differences in vascular calcification
are not well established [32]. Reinforcing these ethnic differences,
AAs are at lower risk for myocardial infarction based on less
coronary artery calcification, and they have significantly lower
rates of myocardial infarction than EAs, provided equal access to
healthcare [33,34]. It has been suggested that AAs may be less
susceptible than whites to hyperglycaemia–induced macrovascular
disease [35]. Thus, these findings may explain the differences
observed in the relationship between vascular disease and DKK1
between our study and the data from Register and colleagues.
Recent data suggest that the association between vascular
calcification and osteoporosis is not simply a consequence of age,
stressing that the co-incidence of vascular calcification with low
bone activity and osteoporosis could be biologically linked. During
the development of vascular calcification, there is a transition of
vascular SMCs towards an osteoblast- like phenotype, which
promotes the mineralization within these structures. In this process
there are several players, including those related to mineral
metabolism, like phosphorus, calcium or parathyroid hormone,
which influences the expression of osteogenic factors [36]. There is
emerging evidence suggesting that some inhibitors of the Wnt
pathway, such as secreted frizzled Proteins 2 and 4 and DKK-1,
may play a role linking vascular calcification and bone loss
[26,27]. AAs manifest a skeletal resistance to the effects of
parathyroid hormone [37,38] and exhibit opposite relationships
between arterial calcification and serum vitamin D concentrations
compared with Europeans [39]. In our opinion, these ethnic
differences in the effects of calciotropic hormones on bone and
vessels may indicate that differences in other pathways, as Wnt
pathway, may be expected according to race. However, this
hypothesis must be confirmed.
There are other differences between the study from Register
and colleagues and ours, which may explain the discrepancy of
results. First, the prevalence of cardiovascular disease is lower,
27%, compared to our study where a 58% of patients had previous
cardiovascular disease. Second, in the study from Register and
colleagues 28,3% of subjects were taking hormonal therapy while
no women were on hormonal therapy in our study. Estradiol and
progesterone has shown to regulate Wnt pathways in endometrial
tissue [40] and brain [41], so an influence of hormonal therapy in
DKK1 concentrations can not be excluded. Finally, despite the
low expected incidence of arterial calcification in AAs, in the study
from Register and colleagues there is a high prevalence of aortic
calcification. Thus, differences between study populations apart
from the ethnicity may influence the discrepancy of results.
There are no previous studies evaluating differences in serum
DKK1 concentrations according to the presence of diabetes. We
did not find differences in DKK1 between T2DM patients and
subjects without diabetes. These results contrast with our previous
data showing higher sclerostin concentrations in the same group of
type 2 diabetes patients [42]. However, serum DKK1 and
sclerostin have shown to be barely correlated [43], as we found
in our sample (data not shown). In addition, the effects of DKK1
and sclerostin may differ due to differences in Kremen binding.
While DKK1 is always an inhibitor of Wnt signaling, the effect of
sclerostin is variable depending on context [44]. Unlike our
previous results about sclerostin, women had higher DKK1
concentrations both in the total sample and in the T2DM group.
Estradiol and progesterone have shown to take part in the
regulation of the Wnt pathways in endometrial tissue [40] and
brain [41], so a sex steroid-induced effect may explain gender
differences in DKK1 although this hypothesis must be confirmed.
Regarding the relationship between bone metabolism and
DKK1 we only found a weak correlation with BMD at lumbar
spine in the total sample, and no relationship with bone turnover
markers, osteoporosis or morphometric vertebral fractures (data
not shown). In addition, lumbar spine BMD may be affected by
aortic calcification. Our findings confirm previous data showing
no relationship between DKK1 and bone turnover markers in
postmenopausal osteoporosis [20]. The relationship between
DKK1 and BMD is not totally established. It has been reported
no relationship with volumetric BMD in Afro-American T2DM
patients [18]. However, is also been described and inverse
relationship between DKK1 and BMD, and higher DKK1
concentrations in patients with osteoporosis [19]. Therefore, in
our opinion the data about serum DKK1 and bone metabolism
are controversial and thus no clear conclusions can be drawn.
Our study has some limitations. First, the cross-sectional design
does not allow to establishing a cause-effect relationship. Second,
the sample size is relatively small and might affect the statistic
power. Our study has also several strengths, as the evaluation of
circulating serum DKK1 in Caucasian patients with T2DM for
the first time, the comparison to non-diabetic subjects and the
evaluation both of bone metabolism and atherosclerotic disease.
In summary, serum levels of DKK1 are elevated in Caucasian
patients with T2DM presenting CVD. These findings suggest that
Wnt signaling pathway is involved in vascular disease in diabetic
subjects. However, the relations of DKK1 with bone metabolism
are inconsistent.
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Figure 2. DKK1 ROC curve for cardiovascular disease.
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